Alopecia areata totalis and universalis: a multicenter review of 132 patients in Spain
- PMID: 27608049
- DOI: 10.1111/jdv.13959
Alopecia areata totalis and universalis: a multicenter review of 132 patients in Spain
Abstract
Background: Alopecia areata totalis (AAT) and universalis (AAU) pose a therapeutic challenge.
Objective: To describe the clinical and epidemiological features, therapeutic response and prognostic factors in a large series of patients diagnosed with AAT and AAU.
Methods: This retrospective multicenter study included patients diagnosed with AAT/AAU with a minimum follow-up of 12 months. Response was assessed based on the regrowth of scalp hair.
Results: In all, 132 patients (92 women and 40 men) - 80 (61%) diagnosed with AAU and 52 (39%) diagnosed with AAT - were included. The median time between the presentation of alopecia areata (AA) and the development of extensive AA was 1 year and it was less than 4 years in 121 patients (91%). There was an initial response to treatment in 64% of patients, although only 14% presented a persistent response. Adverse side effects from the medications used were detected in 33% of patients. The prognostic factors associated with poor response were the presence of AAU and a positive family history of AA.
Conclusions: Treatment of AAT and AAU is challenging. Although an initial regrowth may be achieved, the duration of response is usually short. There were no significant differences on the effectiveness or duration of response between the various systemic therapies.
© 2016 European Academy of Dermatology and Venereology.
Similar articles
-
Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.Clin Exp Dermatol. 2007 Jan;32(1):48-51. doi: 10.1111/j.1365-2230.2006.02256.x. Epub 2006 Sep 27. Clin Exp Dermatol. 2007. PMID: 17004987 Clinical Trial.
-
Five-year experience in the treatment of alopecia areata with DPC.J Eur Acad Dermatol Venereol. 2010 Mar;24(3):264-9. doi: 10.1111/j.1468-3083.2009.03401.x. Epub 2009 Sep 8. J Eur Acad Dermatol Venereol. 2010. PMID: 19744175
-
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.J Cosmet Dermatol. 2019 Aug;18(4):1009-1013. doi: 10.1111/jocd.12883. Epub 2019 Jun 6. J Cosmet Dermatol. 2019. PMID: 31245963
-
Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.JAMA Dermatol. 2018 Oct 1;154(10):1145-1151. doi: 10.1001/jamadermatol.2018.2312. JAMA Dermatol. 2018. PMID: 30073292 Free PMC article.
-
Beard alopecia areata: a multicentre review of 55 patients.J Eur Acad Dermatol Venereol. 2017 Jan;31(1):187-192. doi: 10.1111/jdv.13896. Epub 2016 Sep 12. J Eur Acad Dermatol Venereol. 2017. PMID: 27503140 Review.
Cited by
-
Prognostic Factors in Mexican Patients with Patchy and Other Types of Alopecia Areata.Skin Appendage Disord. 2020 Sep;6(5):296-303. doi: 10.1159/000508925. Epub 2020 Jul 20. Skin Appendage Disord. 2020. PMID: 33088815 Free PMC article.
-
Comorbid Conditions Associated with Alopecia Areata: A Systematic Review and Meta-analysis.Am J Clin Dermatol. 2023 Nov;24(6):875-893. doi: 10.1007/s40257-023-00805-4. Epub 2023 Jul 18. Am J Clin Dermatol. 2023. PMID: 37464249
-
"Turban PUVAsol:" A Simple, Novel, Effective, and Safe Treatment Option for Advanced and Refractory Cases of Alopecia Areata.Int J Trichology. 2018 May-Jun;10(3):124-128. doi: 10.4103/ijt.ijt_95_17. Int J Trichology. 2018. PMID: 30034192 Free PMC article.
-
Alopecia Areata Universalis in the Onset of Autoimmune Polyendocrine Syndrome Type III C.Int J Trichology. 2022 Mar-Apr;14(2):62-64. doi: 10.4103/ijt.ijt_77_20. Epub 2022 Apr 4. Int J Trichology. 2022. PMID: 35531483 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous